Sesame Care vs TelePeptide
Two GLP-1 desks, one scoreboard. We put Sesame Care and TelePeptide head-to-head on the published Brief Score — the same six factors, scored the same way.
Sesame Care
The verdict
Sesame Care takes this head-to-head.
Sesame Care scores 87 to 63 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
That doesn't make TelePeptide a bad call — it's best for readers who want all-in compounded glp-1 (sema/tirz, injectable + oral) from $169/mo; legitscript-certified, 48 states. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Sesame Care | TelePeptide | |
|---|---|---|
| Brief Score | 87/100 (B+) | 63/100 (C) |
| Semaglutide | From $149/mo (brand Wegovy pill) | From $169/mo (starting dose, medication billed separately, compounded) |
| Tirzepatide | Brand Zepbound (price varies) | From $214/mo (starting dose, medication billed separately, compounded) |
| Coverage | Nationwide marketplace | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.
TelePeptide: New to the tracker on 1 August 2026. The published line reads From $169/mo (starting dose, medication billed separately, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.